Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 5
2004 4
2005 7
2006 4
2007 8
2008 11
2009 7
2010 7
2011 8
2012 11
2013 4
2014 4
2015 3
2016 9
2017 2
2018 9
2019 12
2020 2
2021 9
2022 11
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Results by year

Filters applied: . Clear all
Page 1
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis.
Hirani N, MacKinnon AC, Nicol L, Ford P, Schambye H, Pedersen A, Nilsson UJ, Leffler H, Sethi T, Tantawi S, Gravelle L, Slack RJ, Mills R, Karmakar U, Humphries D, Zetterberg F, Keeling L, Paul L, Molyneaux PL, Li F, Funston W, Forrest IA, Simpson AJ, Gibbons MA, Maher TM. Hirani N, et al. Among authors: leffler h. Eur Respir J. 2021 May 27;57(5):2002559. doi: 10.1183/13993003.02559-2020. Print 2021 May. Eur Respir J. 2021. PMID: 33214209 Free PMC article. Clinical Trial.
Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer's disease.
Boza-Serrano A, Ruiz R, Sanchez-Varo R, García-Revilla J, Yang Y, Jimenez-Ferrer I, Paulus A, Wennström M, Vilalta A, Allendorf D, Davila JC, Stegmayr J, Jiménez S, Roca-Ceballos MA, Navarro-Garrido V, Swanberg M, Hsieh CL, Real LM, Englund E, Linse S, Leffler H, Nilsson UJ, Brown GC, Gutierrez A, Vitorica J, Venero JL, Deierborg T. Boza-Serrano A, et al. Among authors: leffler h. Acta Neuropathol. 2019 Aug;138(2):251-273. doi: 10.1007/s00401-019-02013-z. Epub 2019 Apr 20. Acta Neuropathol. 2019. PMID: 31006066 Free PMC article.
Galectins at a glance.
Johannes L, Jacob R, Leffler H. Johannes L, et al. Among authors: leffler h. J Cell Sci. 2018 May 1;131(9):jcs208884. doi: 10.1242/jcs.208884. J Cell Sci. 2018. PMID: 29717004 Review.
Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3.
Mackinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, Delaine T, Simpson AJ, Forbes SJ, Hirani N, Gauldie J, Sethi T. Mackinnon AC, et al. Among authors: leffler h. Am J Respir Crit Care Med. 2012 Mar 1;185(5):537-46. doi: 10.1164/rccm.201106-0965OC. Epub 2011 Nov 17. Am J Respir Crit Care Med. 2012. PMID: 22095546 Free PMC article.
Introduction to galectins.
Leffler H, Carlsson S, Hedlund M, Qian Y, Poirier F. Leffler H, et al. Glycoconj J. 2002;19(7-9):433-40. doi: 10.1023/B:GLYC.0000014072.34840.04. Glycoconj J. 2002. PMID: 14758066 Review.
Galectin-1 induces a tumor-associated macrophage phenotype and upregulates indoleamine 2,3-dioxygenase-1.
Rudjord-Levann AM, Ye Z, Hafkenscheid L, Horn S, Wiegertjes R, Nielsen MAI, Song M, Mathiesen CBK, Stoop J, Stowell S, Straten PT, Leffler H, Vakhrushev SY, Dabelsteen S, Olsen JV, Wandall HH. Rudjord-Levann AM, et al. Among authors: leffler h. iScience. 2023 May 27;26(7):106984. doi: 10.1016/j.isci.2023.106984. eCollection 2023 Jul 21. iScience. 2023. PMID: 37534161 Free PMC article.
Inhibition of galectins with small molecules.
Oberg CT, Leffler H, Nilsson UJ. Oberg CT, et al. Among authors: leffler h. Chimia (Aarau). 2011;65(1-2):18-23. doi: 10.2533/chimia.2011.18. Chimia (Aarau). 2011. PMID: 21469439 Free article. Review.
Selective Monovalent Galectin-8 Ligands Based on 3-Lactoylgalactoside.
Girardi B, Manna M, Van Klaveren S, Tomašič T, Jakopin Ž, Leffler H, Nilsson UJ, Ricklin D, Mravljak J, Schwardt O, Anderluh M. Girardi B, et al. Among authors: leffler h. ChemMedChem. 2022 Feb 4;17(3):e202100514. doi: 10.1002/cmdc.202100514. Epub 2021 Oct 6. ChemMedChem. 2022. PMID: 34613662
Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease.
Zetterberg FR, MacKinnon A, Brimert T, Gravelle L, Johnsson RE, Kahl-Knutson B, Leffler H, Nilsson UJ, Pedersen A, Peterson K, Roper JA, Schambye H, Slack RJ, Tantawi S. Zetterberg FR, et al. Among authors: leffler h. J Med Chem. 2022 Oct 13;65(19):12626-12638. doi: 10.1021/acs.jmedchem.2c00660. Epub 2022 Sep 26. J Med Chem. 2022. PMID: 36154172 Free PMC article.
Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation.
Humphries DC, Mills R, Boz C, McHugh BJ, Hirani N, Rossi AG, Pedersen A, Schambye HT, Slack RJ, Leffler H, Nilsson UJ, Wang W, Sethi T, Mackinnon AC. Humphries DC, et al. Among authors: leffler h. Front Pharmacol. 2022 Aug 8;13:949264. doi: 10.3389/fphar.2022.949264. eCollection 2022. Front Pharmacol. 2022. PMID: 36003515 Free PMC article.
140 results